Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00660179
Registration number
NCT00660179
Ethics application status
Date submitted
14/04/2008
Date registered
17/04/2008
Date last updated
28/09/2015
Titles & IDs
Public title
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Query!
Scientific title
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Query!
Secondary ID [1]
0
0
AC-055-302
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SERAPHIN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cardiovascular
0
0
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - macitentan (ACT-064992)
Treatment: Drugs - macitentan (ACT-064992)
Treatment: Drugs - placebo
Experimental: 1 - Macitentan (ACT-064992) tablet, 3 mg, once daily
Experimental: 2 - Macitentan (ACT-064992) tablet, 10 mg, once daily
Placebo Comparator: 3 - Matching placebo, once daily
Treatment: Drugs: macitentan (ACT-064992)
Tablet, 3 mg dosage, once daily
Treatment: Drugs: macitentan (ACT-064992)
Tablet, 10 mg dosage, once daily
Treatment: Drugs: placebo
Matching placebo, once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event)
Query!
Assessment method [1]
0
0
Morbidity or mortality events were defined as: a) Death; b) Atrial septostomy; c) Lung transplantation; d) Initiation of intravenous (i.v.) or subcutaneous prostanoids, or; e) Other worsening of pulmonary arterial hypertension (PAH).
Other worsening of PAH was defined by the combined occurrence of all the following 3 events:
At least 15% decrease in the 6 minute walk distance from baseline, confirmed by 2 tests performed on separate days, within 2 weeks.
AND worsening of PAH symptoms including at least one of the following:
a) Increase in WHO Functional Class (WHO FC), or no change in patients in WHO FC IV at baseline; b) Appearance or worsening of signs of right heart failure that did not respond to optimized oral diuretic therapy
AND need for new treatment(s) for PAH that included the following: a) Oral or inhaled prostanoids; b) Oral phosphodiesterase inhibitors; c) Endothelin receptor antagonists (only after discontinuation of study treatment; d) i.v. diuretics
Query!
Timepoint [1]
0
0
Up to end of treatment (data presented up to month 36)
Query!
Secondary outcome [1]
0
0
Time to Death Due to PAH or Hospitalisation for PAH up to the End of Treatment (Kaplan-Meier Estimate of Patients Without an Event)
Query!
Assessment method [1]
0
0
Events of PAH or hospitalization for PAH up to the end of treatment included: death due to PAH, or onset of a treatment-emergent adverse event with a fatal outcome due to PAH occurring up to 4 weeks after the end of treatment, or hospitalisation for PAH up to the end of treatment.
Query!
Timepoint [1]
0
0
Up to end of treatment (data presented up to month 36)
Query!
Secondary outcome [2]
0
0
Time to Death Due to Any Cause up to the End of Treatment (Kaplan-Meier Estimate of Patients Without an Event)
Query!
Assessment method [2]
0
0
Events of death due to any cause up to the end of treatment (plus 7 days)
Query!
Timepoint [2]
0
0
Up to end of treatment (data presented up to month 36)
Query!
Secondary outcome [3]
0
0
Time to Death Due to Any Cause up to the End of Study (Kaplan-Meier Estimate of Patients Without an Event)
Query!
Assessment method [3]
0
0
Events of death due to any cause up to the end of study (EOS). The initiation of EOS procedure occurred when the target of 285 events was expected to have been achieved (30 January 2012).
Query!
Timepoint [3]
0
0
Up to end of study (data presented up to month 36)
Query!
Secondary outcome [4]
0
0
Change From Baseline to Month 6 in 6-minute Walk Distance
Query!
Assessment method [4]
0
0
The 6-minute walk test (6MWT) is a non-encouraged test, performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. These guidelines were provided to all sites. For patients who had never performed a 6MWT previously, a training test was required before the qualifying tests for inclusion were performed.
Query!
Timepoint [4]
0
0
Baseline to month 6
Query!
Secondary outcome [5]
0
0
Number of Patients With Improvements in World Health Organization Functional Class From Baseline to Month 6
Query!
Assessment method [5]
0
0
Class I: no limitation of usual physical activity (PA) which does not increase dyspnea, fatigue, chest pain, or presyncope.
Class II: mild limitation of PA. No discomfort at rest. Normal PA increases dyspnea, fatigue, chest pain, or presyncope.
Class III: marked limitation of PA. No discomfort at rest. Less than ordinary activity increases dyspnea, fatigue, chest pain, or presyncope.
Class IV: unable to perform any PA and who may have signs of right ventricular failure. Dyspnea and/or fatigue may be present at rest and symptoms are increased by almost any PA.
Query!
Timepoint [5]
0
0
Baseline to month 6
Query!
Secondary outcome [6]
0
0
Pulmonary Vascular Resistance at Baseline and Month 6
Query!
Assessment method [6]
0
0
In a sub-study, hemodynamic variables were assessed at baseline and Month 6. If the patient had undergone a right heart catheterization during the 3 months prior to randomization, these results were to be used as baseline values, if the background therapy had not changed during the intervening period.
Query!
Timepoint [6]
0
0
Baseline to month 6
Query!
Secondary outcome [7]
0
0
Cardiac Index at Baseline and Month 6
Query!
Assessment method [7]
0
0
In a sub-study, hemodynamic variables were assessed at baseline and Month 6. If the patient had undergone a right heart catheterization during the 3 months prior to randomization, these results were to be used as baseline values, if the background therapy had not changed during the intervening period.
Query!
Timepoint [7]
0
0
Baseline to month 6
Query!
Eligibility
Key inclusion criteria
1. Signed informed consent prior to initiation of any study mandated procedure.
2. Patients with symptomatic pulmonary arterial hypertension (PAH) in modified World
Health Organization (WHO) functional class II to IV.
3. Patients with the following types of pulmonary arterial hypertension (PAH) belonging
to groups 1.1 to 1.3 of the Venice classification:
- Idiopathic (IPAH);
- Familial (FPAH); or
- Related to:
- Collagen vascular disease;
- Simple, congenital systemic-to-pulmonary shunts at least 1 year post
surgical repair;
- Human immunodeficiency virus (HIV) infection; or
- Drugs and toxins.
4. PAH diagnosis confirmed by hemodynamic evaluation performed prior to randomization and
showing all of the following:
- Mean pulmonary artery pressure (mPAP) > 25 mmHg at rest;
- Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic
pressure (LVEDP) < 15 mmHg; and
- Pulmonary vascular resistance (PVR) at rest >= 320 dyn×sec/cm^5.
5. 6-minute walk distance (6MWD) >= 50 m.
6. Men or women > 12 years of age (women of childbearing potential must have a negative
pre-treatment serum pregnancy test and must use a reliable method of contraception).
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. PAH associated with portal hypertension, thyroid disorders, glycogen storage disease,
Gaucher''s disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies,
myeloproliferative disorders or splenectomy.
2. PAH associated with non corrected simple congenital systemic-to-pulmonary shunts, and
combined and complex systemic-to-pulmonary shunts, corrected or non corrected.
3. PAH associated with significant venous or capillary involvement (PCWP > 15 mmHg),
known pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis.
4. Persistent pulmonary hypertension of the newborn.
5. Pulmonary Hypertension belonging to groups 2 to 5 of the Venice classification.
6. Moderate to severe obstructive lung disease: forced expiratory volume in 1
second/forced vital capacity (FEV1/FVC) < 70% and FEV1 < 65% of predicted value after
bronchodilator administration.
7. Moderate to severe restrictive lung disease: total lung capacity (TLC) < 60% of
predicted value.
8. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
9. Estimated creatinine clearance < 30 mL/min
10. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5
times the upper limit of normal.
11. Hemoglobin < 75% of the lower limit of the normal range.
12. Systolic blood pressure < 100 mmHg.
13. Acute or chronic physical impairment (other than dyspnea), limiting the ability to
comply with study requirements.
14. Pregnant or breast-feeding.
15. Known concomitant life-threatening disease with a life expectancy < 12 months.
16. Body weight < 40 kg.
17. Any condition that prevents compliance with the protocol or adherence to therapy.
18. Recently started (< 8 weeks prior to randomization) or planned cardio-pulmonary
rehabilitation program based on exercise.
19. Treatment with endothelin receptor antagonists (ERAs) within 3 months prior to
randomization.
20. Systemic treatment within 4 week prior to randomization with cyclosporine A or
tacrolimus, everolimus, sirolimus (calcineurin or mammalian target of rapamycin (mTOR)
inhibitors).
21. Treatment with cytochrome P3A (CYP3A) inducers within 4 weeks prior to randomization
22. Known hypersensitivity to drugs of the same class as the study drug, or any of their
excipients.
23. Planned treatment, or treatment, with another investigational drug within 1 month
prior to randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
742
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
St. Vincent's Hospital - Darlinghurst, NSW
Query!
Recruitment hospital [2]
0
0
The Alfred Hospital - Melbourne, VIC
Query!
Recruitment hospital [3]
0
0
Royal Brisbane Hospital - Sunshine Coast
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst, NSW
Query!
Recruitment postcode(s) [2]
0
0
3181 - Melbourne, VIC
Query!
Recruitment postcode(s) [3]
0
0
4558 - Sunshine Coast
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maine
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Utah
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Wisconsin
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Buenos Aires
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Cordoba
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Corrientes
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Santa Fe
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Vienna
Query!
Country [31]
0
0
Belarus
Query!
State/province [31]
0
0
Minsk
Query!
Country [32]
0
0
Belarus
Query!
State/province [32]
0
0
Vitebsk
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Leuven
Query!
Country [34]
0
0
Bulgaria
Query!
State/province [34]
0
0
Sofia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Calgary
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Toronto
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Vancouver
Query!
Country [40]
0
0
Chile
Query!
State/province [40]
0
0
Santiago de Chile
Query!
Country [41]
0
0
Chile
Query!
State/province [41]
0
0
Santiago
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Guangdong
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Jiangsu
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Beijing
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Shanghai
Query!
Country [46]
0
0
Colombia
Query!
State/province [46]
0
0
Bogota
Query!
Country [47]
0
0
Colombia
Query!
State/province [47]
0
0
Floridablanca, Santander
Query!
Country [48]
0
0
Croatia
Query!
State/province [48]
0
0
Rijeka
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Clamart
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Montpellier Cedex 5
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Pessac
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Berlin
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Dresden
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Giessen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Greifswald
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Hamburg
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Heidelberg
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Homburg/Saar
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Koln
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Leipzig
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Mainz
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Munich
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Regensburg
Query!
Country [64]
0
0
Hong Kong
Query!
State/province [64]
0
0
Hong Kong
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Budapest
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Szeged
Query!
Country [67]
0
0
India
Query!
State/province [67]
0
0
Ahmedabad
Query!
Country [68]
0
0
India
Query!
State/province [68]
0
0
Delhi
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Hyderabad
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Mumbai
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Pune
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Haifa
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Petach - Tikvah
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Rehovot
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Tel Hashomer
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Tel-Aviv
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Roma
Query!
Country [78]
0
0
Malaysia
Query!
State/province [78]
0
0
Kuala Lumpur
Query!
Country [79]
0
0
Mexico
Query!
State/province [79]
0
0
Mexico City
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Monterrey Nuevo León
Query!
Country [81]
0
0
Netherlands
Query!
State/province [81]
0
0
Nieuwegein
Query!
Country [82]
0
0
Norway
Query!
State/province [82]
0
0
Oslo
Query!
Country [83]
0
0
Peru
Query!
State/province [83]
0
0
Lima
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Krakow
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Warszawa
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Zabrze
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Bucharest
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Ekaterinburg
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Kemerovo
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
Moscow
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
St. Petersburg
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Tomsk
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Yaroslavl
Query!
Country [94]
0
0
Serbia
Query!
State/province [94]
0
0
Belgrade
Query!
Country [95]
0
0
Singapore
Query!
State/province [95]
0
0
Singapore
Query!
Country [96]
0
0
Slovakia
Query!
State/province [96]
0
0
Bratislava
Query!
Country [97]
0
0
South Africa
Query!
State/province [97]
0
0
Johannesburg
Query!
Country [98]
0
0
South Africa
Query!
State/province [98]
0
0
Parow
Query!
Country [99]
0
0
South Africa
Query!
State/province [99]
0
0
Somerset West
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
A Coruna
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Barcelona
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Madrid
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Malaga
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Pontevedra
Query!
Country [105]
0
0
Sweden
Query!
State/province [105]
0
0
Lund
Query!
Country [106]
0
0
Sweden
Query!
State/province [106]
0
0
Uppsala
Query!
Country [107]
0
0
Taiwan
Query!
State/province [107]
0
0
Taichung
Query!
Country [108]
0
0
Taiwan
Query!
State/province [108]
0
0
Taipei
Query!
Country [109]
0
0
Thailand
Query!
State/province [109]
0
0
Bangkok
Query!
Country [110]
0
0
Thailand
Query!
State/province [110]
0
0
Chiang Mai
Query!
Country [111]
0
0
Thailand
Query!
State/province [111]
0
0
Khon Kaen
Query!
Country [112]
0
0
Turkey
Query!
State/province [112]
0
0
Istanbul
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Dnepropetrovsk
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Lviv
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Actelion
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two
different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with
symptomatic PAH. The main study objective is to demonstrate that macitentan (ACT-064992)
prolongs time to the first morbidity or mortality event, and to evaluate the benefit/risk
profile of macitentan (ACT-064992) in the treatment of patients with symptomatic PAH.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00660179
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Loic Perchenet, PhD
Query!
Address
0
0
Actelion
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00660179
Download to PDF